in the United States. This case also provides me an opalysis proceeded uneventfully, and she entered into a hemodialportunity to discuss the current role of the tunneled ysis vascular access monitoring protocol with dynamic venous cuffed catheter in hemodialysis vascular access. pressure testing. On two later occasions, she underwent percuComplications of vascular access are not only a major taneous transluminal angioplasty of a stenotic lesion 2 cm superior to the vein/graft anastomosis. In both instances, venous cause of morbidity in hemodialysis patients, but a major dialysis pressure above the monitor threshold indicated the cost for the end-stage renal disease program. In its latest presence of the lesion. Four months ago, venous dialysis presreport, the United States Renal Data System (USRDS) sure monitoring was changed to monitoring with ultrasound estimated that the costs for access morbidity approach dilution access flow. Her access flow rates continued to decrease on monthly readings, from 1020 ml/min to 750 ml/min over a $8000/patient/year at risk [1] . Remarkably, conservative 4 -month period. Fistulography showed recurrence of the same estimates suggest that this figure represents 17% of the stenotic lesion. Angioplasty was attempted, but the lumen was total spending for hemodialysis patients. Feldman [2, not successfully reconstituted. She was offered elective surgical 3] and others [4] [5] [6] have reported that access-related revision but declined. One month later, her access flow had morbidity accounts for almost 25% of all hospital stays decreased to 680 ml/min, and she presented with a thrombosed arteriovenous graft. Pulse spray thrombolysis revealed a residfor ESRD patients and may contribute to as much as ual 95% outflow stenosis. The patient then elected surgical 50% of all hospitalization costs [2] [3] [4] [5] [6] [7] . Using the prospectively collected data from the Dialysis Outcome Practice Patterns Study (DOPPS), Held has confirmed Feldman's patient care concern, but also an enormous fiscal drain tomosis of the brachial artery with the basilic vein. The disadvantage of this approach is that the vein runs on the on the end-stage renal disease program.
undersurface of the arm and is very difficult to cannulate.
Types of vascular access
Native AV fistulas have the disadvantage of requiring a long maturation time (3 to 6 months) and of not develThe first described, and still the best, form of permanent vascular access is the native arteriovenous fistula oping sufficiently in many older patients, especially diabetics. Thus, early referral, well before the need for dial- [8] [9] [10] . This access, constructed by the anastomosis of a native artery with a native vein, can be created in either ysis, is required to successfully create native AV access in most patients. a side-to-side or an end-to-side fashion. Three types of native AV fistulas can be formed. The radiocephalic Synthetic internal AV fistulas, termed "AV grafts," can be placed in numerous positions in the arms and fistula is formed by the anastomosis of the radial artery with the cephalic vein to form a large forearm vein suitlegs and across the anterior chest wall. The synthetic portion of the graft is usually composed of PTFE [11, able for venipuncture [8] . An alternative type, which can be successfully placed in many patients in whom venous 14-16], a compound synthesized by many manufacturers and formed into both reinforced and nonreinforced conand arterial structures are not suitable for a radiocephalic approach, is a brachiocephalic AV fistula. This access is figurations. Advantages of using PTFE grafts are the short maturation time (3 to 4 weeks) and the multiple formed by the anastomosis of the brachial artery with the cephalic vein above the elbow. Thus, the vein runs potential access sites. Their overwhelming disadvantage is their propensity for venous outflow stenosis caused over the anterior surface of the bicep and is suitable for cannulation [11] [12] [13] . The third type of primary AV by endothelial and fibromuscular hyperplasia [7, 9, 10, 14-16]. fistula, a brachiobasilic AV fistula, is formed by the anas- The third type of permanent vascular access, develsimilar results. At Duke, thrombosis accounted for 84% of all AV access loss, at the Austin Clinic, 85%. Similarly, oped in the late 1980s, is the cuffed, tunneled, internal jugular dialysis catheter [17] [18] [19] [20] [21] [22] [23] [24] [25] . Although capable of the DOQI-derived conclusion from several large investigative efforts into the causes of thrombosis from Duke providing permanent vascular access, its overall performance is inferior to the AV approach in all aspects [7, University, Austin Clinic, and University of California, San Diego, indicate that more than 80% of access failures 9, 10, 20 -25] . Its principal role is as a "bridge" creating immediate access to the circulation and allowing a were caused by outflow stenoses in the venous circulation, 84%, 86%, and 92% at these institutions, respecsmooth clinical transition to the creation of a permanent vascular access.
tively [7, [14] [15] [16] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . These areas of stenosis generally occurred at or near the vein/graft anastomosis, at areas Access failure of vein bifurcation, at areas of calcified venous valves, or at the site of a central venous cannulation [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Failure of permanent vascular access in hemodialysis Fewer than 2% of the total access failures resulted from patients occurs for two reasons. Failure ensues in more arterial stenosis. Fewer than 15% occurred without a than 80% of cases because a thrombotic episode cannot clearly defined anatomic cause. Histologic evaluation rebe resolved [7, 9, 10, [14] [15] [16] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Failure secondary to vealed that endothelial and fibromuscular hyperplasia infection or other complications occurs in approximately 15% to 20% of cases. Two large series of studies by was the leading cause of these venous outflow stenoses, and that 50% to 70% of these stenoses occurred at or different investigating groups (Duke University and Austin Clinic), as collated by the Dialysis Outcome Qualwithin 3 cm of the vein/graft anastomosis (Figs. 1 and 2) [14-16, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Native AV fistulas lacking a vein/graft ity Initiative (DOQI) for vascular access, found strikingly anastomosis had a lower rate of stenosis. Thus, access patency rate than do AV grafts (Fig. 3) . Primary patency reflects patency to the "initial intervention" on the acfailure both in AV fistulas and AV grafts was secondary to fibromuscular and intimal hyperplasia in the venous cess; initial intervention could be thrombolysis or elective angioplasty or surgery. Cumulative patency (defined circulation. The potential causes of the endothelial and fibromuscular hyperplasia will be discussed later in this as patency of the access regardless of the number of interventions) revealed improved performance in AV Forum.
How accurate is our information about the natural graft patency compared to AV fistulas (Fig. 4) ; however, this improvement in AV graft patency was obtained by history of vascular access in hemodialysis patients? The National Kidney Foundation developed evidence-based an increased number of access interventions. The procedures required to maintain AV graft patency were threepractice guidelines on vascular access, the Dialysis Outcome Quality Initiative, and formed the largest data base to sixfold higher than that needed to maintain patency of primary AV fistulas. When center analysis was used available on hemodialysis vascular access [7] . The guideline development team reviewed more than 3500 manu-(selecting data only from centers with an active prospective monitoring and preventive therapy plan) AV fistulas scripts in the course of its work. The working group that constructed the guidelines comprised representatives and AV grafts had nearly equal cumulative patency rates but at the expense of many more corrective procedures from all professional disciplines involved in the formation, maintenance, and care of vascular access [7] . Sevfor AV grafts (Fig. 5) . The 3-year cumulative patency for AV grafts is generally 50%, even at the reporting eral key conclusions were reached. Native AV fistulas (excluding fistulas that fail to mature in the first 60 days centers with the best outcomes [7] . Thus, even at superior centers, only 50% of AV grafts generally survive longer for successful initial cannulation) have a much longer than 3 years. Similar evaluation of studies examining stenosis. Access flow has been carefully validated by using ultrasound dilution (abstract; Depner et al, ibid) cuffed, tunneled catheters found a much shorter lifespan (on average, 12 months) and a much higher complication [41] [42] [43] [44] [45] . Conductance dilution and duplex colorflow Doppler techniques also are available [43, 46, 47] . Colrate than with AV access; thus, the DOQI discouraged the use of these catheters for permanent access [7] .
orflow Doppler has a confounding variable, however: flow measurements are operator-and machine-depenAccess salvage dent and have significant variability [48] . Data obtained by ultrasound dilution suggest that access flow of less Prospective monitoring. Multiple investigators have shown that thrombosis rates and AV graft patency imthan 600 ml/min in PTFE grafts is likely to lead rapidly to access thrombosis. In addition, if the flow is less than prove significantly when prospective screening techniques are used to detect early outflow stenosis (abstract; 1000 ml/min, decrements in access flow of Ͼ15% are equally likely to predict thrombosis and hemodynamiDepner et al, J Am Soc Nephrol 7:1405, 1996) [9, 10, . European investigators have shown significant cally significant stenosis (abstract; Depner et al, ibid) [41] [42] [43] [44] [45] . Monthly access flow monitoring seems to be an benefit in prospective monitoring and ensuing early correction of incipient outflow stenoses of AV fistulas [36, adequate standard. Access flow should be measured at standard times in the hemodialysis treatment to obtain 39]. The theoretical benefits of graft and fistula monitoring are that early fibromuscular hyperplasia can be sucreproducible data and to avoid the variability induced by decreases in cardiac output that are associated with cessfully treated by percutaneous techniques, thereby preventing thrombosis and extending the life of the acultrafiltration. In a study not yet published, we evaluated ultrasound-dilution-determined access flow before and cess. Although not a cure, utilization of monitoring techniques holds the promise of significantly increasing AV after angioplasty in a one-year prospective trial ( Table  3 ). The mean percentage increase in flow following perpatency (Figs. 4 and 5) .
The utility and validity of monitoring techniques for cutaneous transluminal angioplasty (PTA) was 33% in AV fistulas and 41% in AV grafts. Failure to increase detecting venous outflow stenoses in AV grafts and fistulas have gradually improved over the last decade (Table  blood flow greater than 10% by PTA was associated with a high likelihood of further fall in flow and thrombosis. 1). The earliest technique used sequential measurements of dynamic venous dialysis pressure [26] . The approach Corrective angioplasty, although beneficial, failed to restore flow to peak levels. Regardless of the mode of had the advantage of being inexpensive and readily available, but it required slowing blood flows to obtain repetimonitoring, with a single exception [49] , investigators have found significant improvements (40%-80%) in cutive measurements, and use of the venous drip-pressure monitor of the hemodialysis machine resulted in meamulative access patency when prospective monitoring techniques are combined with early correction of outflow surements that were quite variable. Thus, the confounding variables introduced by differences in blood flow, stenosis using either angioplasty or surgical revision [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . length and type of tubing, and type of monitor all needed to be taken into account in using this technique [26, Treatment of outflow stenoses. As I have said, hemodynamically significant venous outflow stenoses must be 28]. This technique identified stenoses after a significant stenosis already had occurred, and was most accurate treated to avoid access thrombosis. If not successfully treated, when a critical reduction in venous diameter for vein/graft stenoses, but it missed stenoses farther up the extremity, where collateral circulation could allow occurs, thrombosis ensues and flow ceases. Hemodynamic significance has been defined by access flow as well dissipation of the venous pressure. Nonetheless, most studies indicated that, despite its shortcomings, the techas by venous dialysis pressure, as I have just discussed [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . To date, no data have convincingly demonnique significantly improved access patency (Table 2) [7, 26, 28] . strated that correcting mild stenoses, that is, venous narrowings without hemodynamic significance, is of any These techniques were supplanted by specialized devices for measuring static venous pressure or venous value. Stenoses of 50% to 70% of lumen diameter respond reasonably well to transluminal angioplasty [7, pressure at blood flows of 0 ml/min [27] . Because these devices avoided the variables induced by blood flow and [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 39] . Mean duration of patency following the first angioplasty of a stenosis of 50% to 70% of lumen diamethe dependency on needle size, and because they used a single standard-pressure transducer, they increased the ter is approximately 6 months [7] . Thus, repetitive angioplasties frequently are necessary. Because intervention accuracy of access monitoring [27] . Measuring static venous dialysis pressure was dramatically simplified rethat does not improve hemodynamic parameters is of little value, successful intervention requires return of cently; it can now be performed without separate devices [40] .
the hemodynamic monitoring parameter, such as access blood flow, to normal. Despite one favorable study [39] , Direct intra-access measures of blood flow are currently the most accurate method for detecting access the DOQI consensus is that the use of metallic stents Dashed line represents AV graft patency. AV fistula patency patency. AV fistula patency excludes fistulas that did not mature suffiexcludes AV fistulas that did not mature sufficiently to allow initial ciently to allow initial cannulation. Graph derived from summed data cannulation. Cumulative patency reflects patency from initial cannulaanalysis from the Vascular Access DOQI [7] . Primary patency reflects tion to abandonment or removal of access. AV graft intervention (procepatency from initial cannulation to first intervention. First intervention dure) rate Ͼ 6 ϫ AV fistula intervention rate. could reflect thrombosis, removal, angioplasty, or surgical revision. vein elastic lesions occurs even after stenting, so ongoing AV graft intervention (procedure) rate Ͼ 3 ϫ AV fistula intervention monitoring is required.
rate.
Not surprisingly, severe outflow stenoses (Ͼ90% of the lumen diameter) generally are more likely to thrombose, and they also are more resistant to percutaneous angioplasty than are less severe stenoses detected progenerally has been of little value in improving access spectively (abstract; Middleton et al, J Am Soc Nephrol patency after angioplasty. Stents prevent surgical 79:A0838, 1414, 1996) [49, 52] . Typically, only a 40% revision of the involved area; thus their value is minimal in peripheral stenoses, where surgical revision is an excel-3-month patency is achieved when angioplasty is em- correct the underlying stenosis results in rapid re-thrombosis within days to weeks [7] .
a Mean access flow was determined by ultrasound dilution
In short, salvage techniques and strategies currently allow us to extend the life of 70% of AV grafts for as long as 3 years (Fig. 5) [7, [36] [37] [38] [39] . These salvage procedures also can be used with AV fistulas, although with less success. The long-term key to access viability, however, is not treating progressive venous stenosis (although that is required today) but preventing the endothelial and fibromuscular hyperplasia that leads to the vast majority of access failures. I will now turn to a discussion of the cellular and subcellular events that lead to venous stenosis, and the possibility of preventing fibromuscular hyperplasia.
The prevailing consensus is that venous stenosis is caused by endothelial injury and vascular smooth muscle hyperplasia in areas where flow turbulence, vessel stretch, and shear stress occur. Many instances of outflow ops at the equally turbulent artery/graft anastomosis or at the site of the artery/vein anastomosis in the AV fistula [7, [14] [15] [16] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Thus, additional factors must be present for hyperplasia to occur. Each venipuncture ployed for these lesions [7] . The surgical data are less of the hemodialysis access forms a localized platelet plug, clear, but preliminary observations suggest that surgical with resultant exposure of the downstream vessel to a revision holds much greater promise, with 6-to 12-month host of platelet-derived cytokines such as plateletpatency rates of 60% to 70% reported in patients with derived growth factor (PDGF). Windus has shown that these severe stenoses (abstract; Middleton et al, ibid) platelets do not deposit directly at the vein/graft anasto- [49, 52] .
mosis [55] . In a series of elegant studies, Himmelfarb Access thrombosis in AV grafts can be successfully and Couper have elucidated the potential cause of this treated with either surgical embolectomy or with pharphenomenon [56] . Previously, Sreedhara and associates macologic or mechanical thrombolysis. Thrombectomy had reported that high-dose dipyridamole decreased acentails incising the graft and inserting an embolectomy cess thrombosis at new, but not at previously established, balloon to clear the clot from the thrombosed access.
AV grafts [57] ; the reasons for this observation are un-"Pulse spray" thrombolysis uses pulsed injections of uroclear. The observations by Himmelfarb and Couper sugkinase via crossed catheters in the clotted access graft gest that the mechanism for this effect might not be until the clot is dissolved (Fig. 7) . Mechanical thrombolysis uses either pulsed saline in a technique similar to related to the effect of dipyridamole on coagulation, but Prospective monitoring for stenoses (see Table 1 ) Therapy of stenoses promise and is currently in clinical trials [59] . That we Percutaneous angioplasty could prevent this injury, rather than merely react to it, Use of stents for elastic stenoses appears a very real possibility for the future.
Surgical revision Prevention Radiation

Summary
Grafts designed to minimize turbulence Gene therapy
Access to large blood vessels capable of providing Pharmacologic therapy rapid extracorporeal blood flow is essential for mainteCytokine inhibitors nance hemodialysis. Access to the circulation is still best provided by native AV fistulas, but AV grafts offer an acceptable alternative. Efforts at encouraging earlier referrals to nephrologists likely will facilitate preservation rather to an inhibitory effect of dipyridamole on plateletof vascular access sites and will allow AV fistulas to be derived cytokines, which stimulate endothelial and placed in a higher percentage of cases; the latter goal fibromuscular hyperplasia in the vessel wall in response was one of the primary recommendations of the DOQI to turbulence injury. The theory that vascular smooth [7] . Recent data from the DOPPS study confirm these muscle hyperplasia reflects a response to injury in which predictions [6] . Patients referred early to a nephrologist PDGF is prominent suggests that vein stenosis is preventare 4 times more likely to have a permanent access placed able. Regardless of the mechanism, these theories open prior to starting dialysis and are 9 times more likely to the possibility that fibromuscular hyperplasia could be have an AV fistula [6] . Increasing the percentage of inhibited by pharmacologic therapy that will inhibit the native AV fistulas among dialysis patients in the US is development and progression of outflow stenosis.
an enormous step forward in decreasing patient morbidAnother approach to the elimination of fibromuscular ity and cost to the ESRD system. A goal of 40% AV hyperplasia is the use of radiation at areas of turbulence fistulas in the US hemodialysis population is attainable to minimize vein/graft stenosis (Table 4) . Prospective over the next 3 years if patients are referred to nephroloclinical studies using these novel therapies represent a gists early. I would argue (as did DOQI) that such refermajor step forward in our thinking and hold great promral should occur when the serum creatinine concentraise for our patients and for the ESRD system. Equally tion reaches 3-4 mg/dl. In addition, strategies for exciting is the promise of gene therapy, as proposed by prospective detection of hemodynamically significant Sukatme in a recent Nephrology Forum [58] . Yet another possibility is that the AV access itself can be modified outflow stenoses, when combined with pro-active correc-tion of this offending lesion, significantly improve access know that venous segments shown radiographically to be 50% blocked are often, but not always, associated patency and should be universally adopted.
The morbidity and costs associated with maintenance with decreased access flow. We also know that when these 50% venous stenoses are corrected, access flow of vascular access constitute an enormous burden both for our patients and for the end-stage renal disease sysimproves significantly and access patency improves. to be a tremendous variability among centers in the us from having to deal with all of the issues that you United States, and also between centers in the US and talked about? abroad, on fistula creation rates. One reason you menDr. Schwab: I think it is unlikely. The latest device tioned is early referral. Could you elaborate on some of that has come on the market that is widely used is the the other reasons why such variability exists? Silastic/silicone cuffed-tunneled cathether. These catheDr. Schwab: We believe that there are multiple reaters serve best as an access bridge to permanent access.
sons why the United States lags in AV fistula formation.
Comparative trials of new AV graft materials have been
One reason is that we tend to have a much higher inciongoing. To date none has emerged as superior to PTFE.
dence of diabetes as a cause of ESRD and a much higher The only new improvement that appears promising is acceptance rate for dialysis than do most other countries. modifying the vein graft anastomosis, by so-called flares Fistulas develop less well in an aging diabetic population. or inserts, which may minimize turbulence. In addition, A second reason is that in the US, patients are referred several companies are starting clinical trials with a totally to nephrologists late in the course of their disease. This subcutaneous hemodialysis catheter port. Nonetheless, late referral has prompted the use of rapidly maturing the Cimino fistula is still by far the most trouble-free rather than slowly maturing accesses. A third reason is long-term access device available. that brachial AV fistulas, which can be formed in older Dr. Harrington: You commented on the difference diabetics whereas Cimino fistulas cannot, are not widely between 50% and 80% stenosis. Fifty percent stenosis used in the United States. of the access marks the time when you would like interThe DOQI panel thought the quickest way to increase vention to begin; 75% to 80% stenosis is where disasters the percentage of patients receiving AV fistulas would are likely to take place fairly soon. Do we know enough be to institute a change in referral patterns. I believe about the rate of progression from 50% to 80% stenosis that nephrologists should, at the very latest, see patients so that if you find someone with 50% stenosis, you can by the time they develop a serum creatinine of 4 mg/dl. state that within 3, 6, or 9 months that stenosis will A goal of 40% AV fistulas in the prevalent hemodialysis become 80%, or is the time course unpredictable? population (compared with 17% currently) is a reasonDr. Schwab: It should be predictable. Unfortunately, able goal for 3 years from now if early referral can be we currently do not have the information at hand to accomplished. make a rational prediction about either the rate of proDr. Singh: Can you update us on anti-endothelial antigression of stenosis or what level of stenosis is associated bodies or protein S deficiency and their association with with a thrombosis. We do know that AV grafts clot graft thrombosis? Dr. Schwab: A series of hypercoagulable states (antireadily at blood flows of less than 600 ml/min. We also phospholopid antibody, etc.) lead to an increase in veno-venous. Similarly, in patients with arterial-arterial bypass, again it is the outflow end that always has the thrombosis in the absence of outflow stenosis in a small subset of patients. I say a "small" subset of patients problem, even in the absence of the needle sticks that bedevil AV fistulas. I always have been amused over because when the DOQI panel tried to determine from the published literature how often thrombosis occurs some of the statistics, while not doubting for a second that AV fistulas are superior to grafts. Patients who tend without significant stenoses, they concluded that this event occurred in fewer than 10% of patients with thromto have the better veins are also younger, more robust patients and thus likely to be transplant patients. On bosis. The working group felt that the principal problem wasn't hypercoagulability but rather failure to deal with the basis of Kaplan-Meiers' statistics, younger transplant patients are recorded at the time they get their transplant the outflow stenosis that caused the thrombosis.
Dr. Andrew S. Levey (Division of Nephrology, New as having patent fistulas. By definition, the fistulas never fail because of the transplant. There are additional biases England Medical Center): You have come to a very logical set of conclusions. I would like to focus on your when access policies differ. If you have an older patient with poor veins, and you have an active peritoneal dialrecommendations for prospective monitoring and early interventions on PTFE grafts. We all agree that randomysis program, sometimes you don't try as hard to keep a graft or a fistula patent. ized trials yield the best kind of evidence. You're making recommendations on the basis of non-randomized trials.
In addition to age and diabetes, what are your thoughts about the import of obesity as American beefs up and Clearly, some of the results are striking but, as you point out, there is a sevenfold increase in the number of procebody mass index soars? I would have thought that at some point, body mass index, perhaps over 30, would dures required to maintain graft access patency. Have you done a cost-effectiveness analysis to compare the become a factor. Finally, is it ever too early to create an AV fistula? Why not put it in whenever the serum strategy of monitoring and early intervention versus access de-clotting and revision only after graft thrombosis? creatinine is elevated? Dr. Schwab: The relationship between patient size Dr. Schwab: Anatole Besarab and colleagues conducted a well-constructed cost analysis of the use of static and access outcome has not, to my knowledge, been studied. Everyone thinks that there's an inverse relationvenous dialysis pressure monitoring [27] . They found that cumulative costs were substantially less with proship, in that as patients become larger, access outcomes are worse. Unfortunately, there's little in the literature spective intervention than with a conservative approach because aggressive intervention minimized unscheduled to prove the point. Question two is, "when do you place an AV fistula?" The DOQI workgroup concluded that, thrombotic events and minimized hospital days. That is the only study that has specifically addressed cost. The unlike an AV graft, there was little evidence that placing an AV fistula early caused premature access failure. question you are asking is, are we merely substituting one procedure for another? We might be. I would also
There was also very little evidence that placing an AV fistula early led to significant cardiovascular abnormaliargue that even if that were the case, we are substituting an elective procedure for an urgent and unscheduled ties. The working group concluded that by placing a primary AV fistula in a patient with a serum creatinine procedure.
Dr. Richard Roher (Chief, Division of Surgical of 4 mg/dl, one optimizes the chance of maintaining a functioning AV fistula when the need for dialysis arises. Transplants, New England Medical Center): I congratulate you on a thorough review of the AV access field.
Preliminary observations from the DOPPS study suggest that early referral to a nephrologist dramatically inFrom my perspective I have no major argument with your conclusions. I might add as well that dialysis patients creases the likelihood of an AV fistula being present when dialysis is started [6] . all should have their access planning integrated with their transplant plans, because many could even avoid Dr. Harrington: DOQI recommends referral to a nephrologist when the serum creatinine is 4 mg/dl. The dialysis access. Also, my view is that we should view catheters in the great veins as completely unnecessary recommendations don't explicitly suggest placing a fistula around the time the patient first sees a nephrologist. even though we know that in the real world they are needed from time to time. But have suggested that increasing the hematocrit as high as 36% has any significant effect on the thrombosis rate. don't form AV access as well as nondiabetics because of either arterial or venous problems or both is unclear
The Normal Hematocrit Cardiac Trial showed that patients randomized to a hematocrit of 42% Ϯ 3% had a to me. Perhaps Dr. Rohrer has an opinion.
Dr. Rohrer: I think there is a metabolic defect in statistically greater likelihood of access thrombosis than did those randomized to the lower hematocrit target [61] . these patients, and also in lupus patients, that affects their vessels. But I cannot define it well. There is some-
The reason for the greater thrombosis rate, be it more intravenous iron, much higher Epo doses, or a higher thing about their vessels, too fragile or too small in a predictable sort of way time after time, that makes them hematocrit, is unknown. Second, the DOQI panel for anemia suggested that we should convert to subcutanesimply fail to mature.
Dr. Meyer: What's your approach to the patient ous Epo dosing, primarily because we will save substantial sums of money while arriving at the same hematocrit whose fistula doesn't develop? Do you work that patient up? Do you do an ultrasound? Do you do a venogram? target. Dr. King: You alluded to the data from Jonathan Or do you just wait a few weeks to months and then go higher in the arm or go to a graft?
Himmelfarb on endothelial hyperplasia [56] , but of course the pathologic lesion is primarily vascular smooth Dr. Schwab: The literature suggests that primary AV fistulas can be salvaged by identifying and tying off collatmuscle hyperplasia. In your discussion, you suggested that the hyperplasia is mediated by growth factors, ineral vessels so that the blood flow is forced to flow along a single vein. Our practice is, if a radiocephalic fistula cluding PDGF. Could you elaborate on that hypothesis and the purported cytokines involved? does not develop in 3 months, we either revise it as I outlined earlier or form a brachiocephalic fistula on the Dr. Schwab: Himmelfarb demonstrated recently in Kidney International that PDGF stimulated smooth mussame side.
Dr. Ronald D. Perrone (Division of Nephrology, cle proliferation in cell culture [56] . He then showed that you could inhibit this hyperplasia almost completely by New England Medical Center): Could you comment on how you deliver bioactive agents into a graft? What sort the use of pharmacologic doses of dipyridamole. Dr. Al Shohaib: When you say that patients should of technology has been developed to do this? Are they systemically administered, or are they administered lohave access established when the creatinine is around 4 mg/dl, shouldn't one take into consideration the rate of cally, continuously infused, impregnated, or how?
Dr. Schwab: The agents that are coming to trial now progression of the renal disease? One patient with a serum creatinine of 4 mg/dl might require dialysis within all are substances that are taken orally, once or twice per day. Gene constructs, assuming that they come into a few months, whereas another might remain stable for a few years. use, presumably will be delivered directly to vein anastomoses by ultrasound-directed puncture or by impregnaMy second question is about patients with polycystic
